Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aurinia Pharmaceuticals ( (AUPH) ) has issued an update.
Aurinia Pharmaceuticals announced it will report its financial results for the three and nine months ended September 30, 2025, and provide an update on its recent business progress on November 4, 2025. This announcement is significant as it may offer insights into the company’s financial health and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AUPH) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals demonstrates strong financial performance and positive earnings call highlights, contributing to a favorable outlook. However, the stock’s high valuation and technical indicators suggest caution. The absence of corporate events further consolidates the focus on financial and earnings performance.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company that specializes in developing therapies for autoimmune diseases with significant unmet medical needs. The company is known for LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis, and is also working on aritinercept for potential autoimmune disease treatments.
Average Trading Volume: 1,791,126
Technical Sentiment Signal: Buy
Current Market Cap: $1.73B
For a thorough assessment of AUPH stock, go to TipRanks’ Stock Analysis page.